Testosterone / working resource
Primary source desk
Keep the original documents and the limits of their conclusions within reach.
Start with the product-specific question
How low testosterone is diagnosed
Testosterone replacement, with the evidence and its limits in plain view. What should I know about how low testosterone is diagnosed?
Open the Testosterone library ↗In TRAVERSE, the primary endpoint (cardiovascular death, nonfatal heart attack or nonfatal stroke) occurred in 7.0% on testosterone and 7.3% on placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17), meeting noninferiority; mean treatment was 21.7 months and mean follow-up 33.0 months.
Read the original record ↗
The original record comes first.
These are starting points for the Testosterone library. Read the source's exact question, product, population and date. A source can be authoritative for one claim and irrelevant to another.
FDA: human drug compounding ↗
Keep claims and sources together.
In TRAVERSE, the primary endpoint (cardiovascular death, nonfatal heart attack or nonfatal stroke) occurred in 7.0% on testosterone and 7.3% on placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17), meeting noninferiority; mean treatment was 21.7 months and mean follow-up 33.0 months.
Supporting record ↗The ACP evidence review (38 RCTs of at least 6 months plus 20 observational studies) found small improvements in sexual functioning and quality of life, and little to no effect on physical functioning, depressive symptoms, energy and vitality, or cognition.
Supporting record ↗In the Testosterone Trials, testosterone significantly increased sexual activity, sexual desire and erectile function and slightly improved mood and depressive symptoms, but had no significant benefit on vitality (fatigue scale).
Supporting record ↗A network meta-analysis of 29 placebo-controlled RCTs (3,393 men) found every testosterone form raised mean hematocrit; intramuscular enanthate/cypionate raised it 4.0% (95% CI 2.9 to 5.1), significantly more than the patch.
Supporting record ↗The current Depo-Testosterone label states that safety and efficacy in men with age-related (late-onset) hypogonadism have not been established; a generic cypionate label revised June 2026 carries the same statement.
Supporting record ↗These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.